Cargando…

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling

BACKGROUND: Checkpoint inhibitor therapy of cancer has led to markedly improved survival of a subset of patients in multiple solid malignant tumor types, yet the factors driving these clinical responses or lack thereof are not known. We have developed a mechanistic mathematical model for better unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Butner, Joseph D, Martin, Geoffrey V, Wang, Zhihui, Corradetti, Bruna, Ferrari, Mauro, Esnaola, Nestor, Chung, Caroline, Hong, David S, Welsh, James W, Hasegawa, Naomi, Mittendorf, Elizabeth A, Curley, Steven A, Chen, Shu-Hsia, Pan, Ping-Ying, Libutti, Steven K, Ganesan, Shridar, Sidman, Richard L, Pasqualini, Renata, Arap, Wadih, Koay, Eugene J, Cristini, Vittorio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629426/
https://www.ncbi.nlm.nih.gov/pubmed/34749885
http://dx.doi.org/10.7554/eLife.70130
_version_ 1784607204749344768
author Butner, Joseph D
Martin, Geoffrey V
Wang, Zhihui
Corradetti, Bruna
Ferrari, Mauro
Esnaola, Nestor
Chung, Caroline
Hong, David S
Welsh, James W
Hasegawa, Naomi
Mittendorf, Elizabeth A
Curley, Steven A
Chen, Shu-Hsia
Pan, Ping-Ying
Libutti, Steven K
Ganesan, Shridar
Sidman, Richard L
Pasqualini, Renata
Arap, Wadih
Koay, Eugene J
Cristini, Vittorio
author_facet Butner, Joseph D
Martin, Geoffrey V
Wang, Zhihui
Corradetti, Bruna
Ferrari, Mauro
Esnaola, Nestor
Chung, Caroline
Hong, David S
Welsh, James W
Hasegawa, Naomi
Mittendorf, Elizabeth A
Curley, Steven A
Chen, Shu-Hsia
Pan, Ping-Ying
Libutti, Steven K
Ganesan, Shridar
Sidman, Richard L
Pasqualini, Renata
Arap, Wadih
Koay, Eugene J
Cristini, Vittorio
author_sort Butner, Joseph D
collection PubMed
description BACKGROUND: Checkpoint inhibitor therapy of cancer has led to markedly improved survival of a subset of patients in multiple solid malignant tumor types, yet the factors driving these clinical responses or lack thereof are not known. We have developed a mechanistic mathematical model for better understanding these factors and their relations in order to predict treatment outcome and optimize personal treatment strategies. METHODS: Here, we present a translational mathematical model dependent on three key parameters for describing efficacy of checkpoint inhibitors in human cancer: tumor growth rate (α), tumor-immune infiltration (Λ), and immunotherapy-mediated amplification of anti-tumor response (µ). The model was calibrated by fitting it to a compiled clinical tumor response dataset (n = 189 patients) obtained from published anti-PD-1 and anti-PD-L1 clinical trials, and then validated on an additional validation cohort (n = 64 patients) obtained from our in-house clinical trials. RESULTS: The derived parameters Λ and µ were both significantly different between responding versus nonresponding patients. Of note, our model appropriately classified response in 81.4% of patients by using only tumor volume measurements and within 2 months of treatment initiation in a retrospective analysis. The model reliably predicted clinical response to the PD-1/PD-L1 class of checkpoint inhibitors across multiple solid malignant tumor types. Comparison of model parameters to immunohistochemical measurement of PD-L1 and CD8+ T cells confirmed robust relationships between model parameters and their underlying biology. CONCLUSIONS: These results have demonstrated reliable methods to inform model parameters directly from biopsy samples, which are conveniently obtainable as early as the start of treatment. Together, these suggest that the model parameters may serve as early and robust biomarkers of the efficacy of checkpoint inhibitor therapy on an individualized per-patient basis. FUNDING: We gratefully acknowledge support from the Andrew Sabin Family Fellowship, Center for Radiation Oncology Research, Sheikh Ahmed Center for Pancreatic Cancer Research, GE Healthcare, Philips Healthcare, and institutional funds from the University of Texas M.D. Anderson Cancer Center. We have also received Cancer Center Support Grants from the National Cancer Institute (P30CA016672 to the University of Texas M.D. Anderson Cancer Center and P30CA072720 the Rutgers Cancer Institute of New Jersey). This research has also been supported in part by grants from the National Science Foundation Grant DMS-1930583 (ZW, VC), the National Institutes of Health (NIH) 1R01CA253865 (ZW, VC), 1U01CA196403 (ZW, VC), 1U01CA213759 (ZW, VC), 1R01CA226537 (ZW, RP, WA, VC), 1R01CA222007 (ZW, VC), U54CA210181 (ZW, VC), and the University of Texas System STARS Award (VC). BC acknowledges support through the SER Cymru II Programme, funded by the European Commission through the Horizon 2020 Marie Skłodowska-Curie Actions (MSCA) COFUND scheme and the Welsh European Funding Office (WEFO) under the European Regional Development Fund (ERDF). EK has also received support from the Project Purple, NIH (U54CA210181, U01CA200468, and U01CA196403), and the Pancreatic Cancer Action Network (16-65-SING). MF was supported through NIH/NCI center grant U54CA210181, R01CA222959, DoD Breast Cancer Research Breakthrough Level IV Award W81XWH-17-1-0389, and the Ernest Cockrell Jr. Presidential Distinguished Chair at Houston Methodist Research Institute. RP and WA received serial research awards from AngelWorks, the Gillson-Longenbaugh Foundation, and the Marcus Foundation. This work was also supported in part by grants from the National Cancer Institute to SHC (R01CA109322, R01CA127483, R01CA208703, and U54CA210181 CITO pilot grant) and to PYP (R01CA140243, R01CA188610, and U54CA210181 CITO pilot grant). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
format Online
Article
Text
id pubmed-8629426
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-86294262021-12-01 Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling Butner, Joseph D Martin, Geoffrey V Wang, Zhihui Corradetti, Bruna Ferrari, Mauro Esnaola, Nestor Chung, Caroline Hong, David S Welsh, James W Hasegawa, Naomi Mittendorf, Elizabeth A Curley, Steven A Chen, Shu-Hsia Pan, Ping-Ying Libutti, Steven K Ganesan, Shridar Sidman, Richard L Pasqualini, Renata Arap, Wadih Koay, Eugene J Cristini, Vittorio eLife Medicine BACKGROUND: Checkpoint inhibitor therapy of cancer has led to markedly improved survival of a subset of patients in multiple solid malignant tumor types, yet the factors driving these clinical responses or lack thereof are not known. We have developed a mechanistic mathematical model for better understanding these factors and their relations in order to predict treatment outcome and optimize personal treatment strategies. METHODS: Here, we present a translational mathematical model dependent on three key parameters for describing efficacy of checkpoint inhibitors in human cancer: tumor growth rate (α), tumor-immune infiltration (Λ), and immunotherapy-mediated amplification of anti-tumor response (µ). The model was calibrated by fitting it to a compiled clinical tumor response dataset (n = 189 patients) obtained from published anti-PD-1 and anti-PD-L1 clinical trials, and then validated on an additional validation cohort (n = 64 patients) obtained from our in-house clinical trials. RESULTS: The derived parameters Λ and µ were both significantly different between responding versus nonresponding patients. Of note, our model appropriately classified response in 81.4% of patients by using only tumor volume measurements and within 2 months of treatment initiation in a retrospective analysis. The model reliably predicted clinical response to the PD-1/PD-L1 class of checkpoint inhibitors across multiple solid malignant tumor types. Comparison of model parameters to immunohistochemical measurement of PD-L1 and CD8+ T cells confirmed robust relationships between model parameters and their underlying biology. CONCLUSIONS: These results have demonstrated reliable methods to inform model parameters directly from biopsy samples, which are conveniently obtainable as early as the start of treatment. Together, these suggest that the model parameters may serve as early and robust biomarkers of the efficacy of checkpoint inhibitor therapy on an individualized per-patient basis. FUNDING: We gratefully acknowledge support from the Andrew Sabin Family Fellowship, Center for Radiation Oncology Research, Sheikh Ahmed Center for Pancreatic Cancer Research, GE Healthcare, Philips Healthcare, and institutional funds from the University of Texas M.D. Anderson Cancer Center. We have also received Cancer Center Support Grants from the National Cancer Institute (P30CA016672 to the University of Texas M.D. Anderson Cancer Center and P30CA072720 the Rutgers Cancer Institute of New Jersey). This research has also been supported in part by grants from the National Science Foundation Grant DMS-1930583 (ZW, VC), the National Institutes of Health (NIH) 1R01CA253865 (ZW, VC), 1U01CA196403 (ZW, VC), 1U01CA213759 (ZW, VC), 1R01CA226537 (ZW, RP, WA, VC), 1R01CA222007 (ZW, VC), U54CA210181 (ZW, VC), and the University of Texas System STARS Award (VC). BC acknowledges support through the SER Cymru II Programme, funded by the European Commission through the Horizon 2020 Marie Skłodowska-Curie Actions (MSCA) COFUND scheme and the Welsh European Funding Office (WEFO) under the European Regional Development Fund (ERDF). EK has also received support from the Project Purple, NIH (U54CA210181, U01CA200468, and U01CA196403), and the Pancreatic Cancer Action Network (16-65-SING). MF was supported through NIH/NCI center grant U54CA210181, R01CA222959, DoD Breast Cancer Research Breakthrough Level IV Award W81XWH-17-1-0389, and the Ernest Cockrell Jr. Presidential Distinguished Chair at Houston Methodist Research Institute. RP and WA received serial research awards from AngelWorks, the Gillson-Longenbaugh Foundation, and the Marcus Foundation. This work was also supported in part by grants from the National Cancer Institute to SHC (R01CA109322, R01CA127483, R01CA208703, and U54CA210181 CITO pilot grant) and to PYP (R01CA140243, R01CA188610, and U54CA210181 CITO pilot grant). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. eLife Sciences Publications, Ltd 2021-11-09 /pmc/articles/PMC8629426/ /pubmed/34749885 http://dx.doi.org/10.7554/eLife.70130 Text en © 2021, Butner et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Medicine
Butner, Joseph D
Martin, Geoffrey V
Wang, Zhihui
Corradetti, Bruna
Ferrari, Mauro
Esnaola, Nestor
Chung, Caroline
Hong, David S
Welsh, James W
Hasegawa, Naomi
Mittendorf, Elizabeth A
Curley, Steven A
Chen, Shu-Hsia
Pan, Ping-Ying
Libutti, Steven K
Ganesan, Shridar
Sidman, Richard L
Pasqualini, Renata
Arap, Wadih
Koay, Eugene J
Cristini, Vittorio
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
title Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
title_full Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
title_fullStr Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
title_full_unstemmed Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
title_short Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
title_sort early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629426/
https://www.ncbi.nlm.nih.gov/pubmed/34749885
http://dx.doi.org/10.7554/eLife.70130
work_keys_str_mv AT butnerjosephd earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT martingeoffreyv earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT wangzhihui earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT corradettibruna earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT ferrarimauro earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT esnaolanestor earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT chungcaroline earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT hongdavids earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT welshjamesw earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT hasegawanaomi earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT mittendorfelizabetha earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT curleystevena earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT chenshuhsia earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT panpingying earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT libuttistevenk earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT ganesanshridar earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT sidmanrichardl earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT pasqualinirenata earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT arapwadih earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT koayeugenej earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling
AT cristinivittorio earlypredictionofclinicalresponsetocheckpointinhibitortherapyinhumansolidtumorsthroughmathematicalmodeling